---
title: "Rocket Pharma Is A Buy At These Prices With Promising Data"
date: "2025-02-12 23:40:12"
summary: "Richard Drury  I interviewed Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) CEO Dr. Gaurav Shah a year ago, but apart from that, I haven’t covered it in 2 years. My last coverage was from February 2023. Back in 2024, RCKT had"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Five stacks of coloured coins with a graph line above](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w750) 



Richard Drury





I [interviewed](https://seekingalpha.com/instablog/48328311-avisol-capital-partners/5992312-interview-dr-gaurav-shah-md-ceo-of-rocket-pharmaceuticals) **Rocket Pharmaceuticals, Inc.’s** (NASDAQ:[RCKT](https://seekingalpha.com/symbol/RCKT "Rocket Pharmaceuticals, Inc.")) CEO Dr. Gaurav Shah a year ago, but apart from that, I haven’t covered it in 2 years. My last [coverage](https://seekingalpha.com/author/avisol-capital-partners/analysis?ticker=RCKT) was from February 2023. Back in 2024, RCKT had

[seekalpha_articles](https://seekingalpha.com/article/4757552-rocket-pharma-is-a-buy-at-these-prices-with-promising-data)
